In the mid-1980s researchers confidently predicted that an effective vaccine against Plasmodium falciparum, the most dangerous species of malaria parasite, would be available within a decade. Twenty years later, although a number of clinical and field trials of various malaria vaccines have taken place or are ongoing, the promise of an effective vaccine-even as an adjunct measure to accompany insecticide-treated bed nets and mosquito control-is as distant as ever. This Essay summarizes some of the difficulties that scientists face in developing a vaccine against one of the greatest scourges of the developing world, surveys previous and ongoing vaccine efforts, and discusses future directions that will be influenced by the availability of the full genome sequence of P. falciparum (Gardner et al., 2002) .
Obstacles to a Malaria Vaccine
Estimates of the annual death toll due to malaria infection vary, but all indicate that this is a devastating and underestimated disease affecting the tropical regions of the world that may kill as many as 2.5 million people annually (Snow et al., 2005) . Furthermore, the impact of malaria on the global economy should not be overlooked. The 2004 Copenhagen Consensus of expert economists (http://www.copenhagenconsensus.com/Default.aspx) concluded that effective malaria control ranked number 4 on the list of measures that would favorably impact the world economy. One route to address the huge burden imposed by malaria on the developing world is vaccination. However, many obstacles have to be surmounted to create a vaccine capable of protecting against this complex pathogen.
Chief among these are the following. (1) The life cycle of the parasite is extremely intricate-at different stages of its life cycle, the Plasmodium parasite presents complex immunologically distinct surfaces to the host immune system (see Figure  1) . Thus, any vaccine consisting of a single protein component needs to invoke innate and adaptive immune responses and immunological memory. (2) The blood stage of Plasmodium causes the many pathological manifestations associated with malaria infection, and thus proteins expressed during this stage should include good candidate components for a vaccine. However, while resident in host erythrocytes, P. falciparum undergoes antigenic variation. The principal parasite protein and virulence factor expressed on the surface of host erythrocytes known to undergo antigenic variation is PfEMP1. This multimodular adhesin protein is encoded by 50-60 var genes, as revealed by the complete Plasmodium genome sequence (Gardner et al., 2002) . It is responsible for parasite sequestration in deep tissue vasculature through binding to endothelial surface proteins. The var genes are expressed in a clonal fashion, but the expressed gene may switch in any given individual parasite, and the individual PfEMP1 adhesin modules (known as DBL and CIDR) mediate sequestration and have unique binding specificities. Therefore, the adhesion profile of the parasite and resulting pathology depends upon the specificities of the constituent DBL and CIDR domains of the expressed var gene and the distribution of the target host receptors. Typical sequestration-associated pathologies involve the brain (cerebral malaria) and the placenta (pregnancy associated malaria, PAM). Vaccination to prevent sequestration in the host vasculature would aim to generate antibodies that would prevent the parasite ligand-host receptor interaction. Although potentially desirable, it is probably not possible to immunize humans effectively against all of the potential >250 adhesin domains of PfEMP1, especially as there is an enhanced rate of recombination among var genes. (3) The third obstacle is lack of correlates of immune protection. It is not completely clear what type of immunological response would be effective against the malaria parasite. Most likely protection will involve a combination of antibody-and cellmediated immune responses. For example, it is well-established that antibodies of clinically immune individuals alone can prevent parasite proliferation in host red blood cells (Cohen and Butcher, 1970) , and that protection against the sporozoite stage involves both antibody-and cell-mediated immunity. Repeated and prolonged exposure to malaria parasites invokes immunity but it is not sterilizing, that is, it does not eradicate all parasites and does not provide complete protection against future challenge. Therefore, this type of immunity should be considered preimmunity, particularly as it is short-lived and memory T cells are not appropriately engaged.
Malaria: New Vaccines for Old?
Andrew Waters 1, Current Strategies for Vaccine Development So should a vaccine against malaria attempt to achieve sterilizing immunity or should its goal be to prevent malaria-associated pathology (such as cerebral malaria or pregnancyassociated malaria), termed an antidisease approach? Pregnancy-associated malaria in particular lends itself to this approach because adherence of the parasite-infected erythrocytes to endothelial cells of the placenta is known to be due to the interaction of largely one DBL domain of PfEMP1 (DBL3-γ subunit of VAR2CSA) with the placenta-specific sugar chondroitin sulfate A. Thus, immunization with DBL3-γ should induce antibodies that would block binding of PfEMP1 carrying this domain to the placenta (Viebig et al., 2005) . Immunization to control disease, although currently focused on individual pathologies, would more closely resemble the natural nonsterilizing immunity that develops in people in sub-Saharan Africa who are constantly exposed to the Plasmodium parasite.
There are many vaccine candidates and strategies for inducing immunity against malaria parasites already under consideration (reviewed in Targett, 2005) ; summarized at http:// w w w.who.int /vaccine _ research / documents/en/malaria_table.pdf; for a review of human trials see Graves and Gelbland, 2006) . The vast majority of these have a common theme in that they attempt to use a single or limited number of recombinant parasite products (mainly "antigens") to induce immunity. Besides immunization to diminish the disease, vaccination may seek to control parasite proliferation and survival. In the latter, parasite invasion of host cells may be blocked and parasite numbers reduced at three different stages of the life cycle: pre-erythrocytic, erythrocytic, and development in the mosquito vector (see Figure  1 ). However, there are drawbacks to targeting each individual stage (see legend to Figure 1 ).
Although true correlates of immune protection in the host against malaria infection are absent, both antibody and cell-mediated immunity (both CD4 + and CD8 + T cell responses) are (1) Pre-erythrocytic vaccination aims to prevent entry of sporozoites into host liver cells (hepatocytes) and their subsequent development to liver schizonts. Blocking of invasion may be achieved with antibodies and abrogation of development by cell-mediated immunity. The biggest drawback is that a single sporozoite escaping attenuation may cause a fully pathogenic blood stage infection. This happened in clinical trials of the latest antisporozoite vaccine called RTS,S (Alonso et al., 2005) . (2) Erythrocytic vaccination targets the life-cycle stage that invades and develops in host erythrocytes, which is associated with disease pathology. Vaccination to block parasite development in host red blood cells depends on generating antibodies to prevent erythrocyte invasion by merozoites released from schizonts (of liver or blood origin). Antibodies target key merozoite surface proteins (such as MSP-1) or those contained in specialized organelles associated with invasion (such as AMA-1). The biggest drawback is the limited window of opportunity that exists to prevent merozoite invasion of the erythrocyte (merozoites are only outside erythrocytes for less than 2 min) and the fact that P. falciparum uses alternative invasion pathways. (3) Transmission-blocking vaccination seeks to stimulate the production of antibodies that prevent either fertilization of the gametes in the blood meal taken into the mosquito midgut or the development of the zygote to an ookinete and its successful invasion of the mosquito midgut wall. The biggest drawback is that this strategy is altruistic, providing a herd benefit by protecting future victims from the mosquito's bite. (4) The fourth strategy, anti-disease vaccination, aims for example to block the sequestration of parasite-infected erythrocytes (which causes much of the serious pathology of malaria) by preventing the parasite surface protein PfEMP1 from interacting with various vascular endothelial cell-surface receptors. A successful vaccine that is not based upon attenuating the whole parasite is likely to contain components of the first three categories. Anti-disease vaccination may be of use alone but would also be a desirable addition to a polyvalent, multicomponent vaccine formulation. required. A number of different vaccination strategies to generate such responses from single or more likely a combination of candidate antigens from different life-cycle stages are underway. The most promising strategy appears to be a heterologous prime-boost approach in which priming of the immune response to chosen antigens is achieved using DNA expression vectors (plasmid or attenuated viral vectors, AVV) followed by boosting using AVV expressing the same antigens (reviewed in Targett, 2005) . In total there are about 50 vaccine candidates against P. falciparum that are currently under development (http://www.who.int/ vaccine_research/documents/en/ malaria_table.pdf), and all pre-date publication of the complete genome sequence of Plasmodium. Investment in pipelines for malaria vaccine development has been relatively poor, and although strategies for certain candidates may have been abandoned, all 50 vaccine candidates remain in the framework for continued development. But the complexity of the parasite and the problem of the lack of true correlates of disease are coming back to haunt researchers. Although all candidates were chosen on the basis of their ability to elicit some form of inhibitory immune response against the parasite (as measured in vitro and, for some, in animal models), there is little further basis for rational vaccine design. Obviously, it would be prohibitively expensive to take the existing 50 candidates through full multiphase clinical trial evaluation. Without new investment and dropping some of the current candidates, it is hard to see how funds can be made available for the further development of any new candidate vaccines that might be uncovered by Plasmodium genome and post-genome research. Such decisions perhaps represent one of the community's greatest current challenges.
Vaccine Research in the PostGenome Era What have P. falciparum genome and post-genome analyses provided in the way of new vaccine candidates?
The genomics approach has been helped substantially by comparative data from genome characterization and post-genome studies of other species of malaria parasites, most notably those of rodents. These rodent malaria parasites-principally Plasmodium berghei, Plasmodium yoelii, and Plasmodium chabaudiserve as useful models for the entire parasite life cycle and for interactions among the host, the parasite, and its insect vector, the mosquito. Each rodent Plasmodium species is thought to share with P. falciparum a core of 4500 genes (of a total genome complement of 5300 to 5500 genes). These shared genes include orthologs of many of the leading human parasite vaccine candidates (Hall et al., 2005) . In the research community's Plasmodium genome database-PlasmoDB (www.plasmo db.org)-over 10% (579 of ?5500) of annotated P. falciparum genes are predicted to encode proteins containing signal peptides. These proteins enter the parasite endoplasmic reticulum and are transported to the parasite surface, or the surface of the occupied host erythrocyte, or to parasite organelles (such as the rhoptries, micronemes, and dense granules required for invasion of new host erythrocytes).
Of these proteins, transcriptome and proteome data indicate that only 197 are expressed in the life-cycle stages targeted for vaccine development: 43 (32) proteins are expressed in gametocytes, 57 (42) are sporozoite specific, and 94 (61) proteins are uniquely expressed in either the young or late schizont or merozoite stages (numbers in parentheses indicate the number of orthologs found in P. berghei). In principle, each one of the surface proteins might be a vaccine candidate if the vaccine strategy aims to stimulate the production of antibodies that might interfere with the function of that protein. Additional post-genome analyses have pinpointed potential candidate proteins from these groups that are associated with surface/rhoptry transport structures called Maurer's clefts in the parasiteinfected erythrocytes (Sam-Yellowe et al., 2004; Vincensini et al., 2005) , or with schizont/merozoite lipid rafts enriched with GPI-anchored proteins (Sanders et al., 2005) . Finally, genome and post-genome comparisons have been exploited to identify genes that contain a signal peptide, are expressed in the blood stage, and are undergoing accelerated evolution (106 in total), which indicates a response to selective pressure such as recognition by the immune system, a property that is arguably desirable in a vaccine candidate (Hall et al., 2005) .
Post-genome analyses have also provided fresh insights into existing vaccine candidates. For example, the AMA-1 protein-which is released from micronemes to the surface of the invasive merozoite after schizont rupture-has been a leading blood-stage vaccine candidate. Both monoclonal and polyclonal antibodies against AMA-1 block erythrocyte invasion in vitro, and there is good evidence in animal models for AMA-1's efficacy as a vaccine candidate (Deans et al., 1988; Crewther et al., 1996) . Both proteome and transcriptome analyses (LeRoch et al., 2003) indicate that AMA-1 is expressed not only in merozoites but also in sporozoites, stimulating research demonstrating that those AMA-1-specific antibodies that prevent erythrocyte invasion also prevent sporozoite infection of hepatocytes (Silvie et al., 2004) . Therefore, AMA-1 may be a pre-erythrocytic as well as a bloodstage vaccine candidate.
The global gene analyses emphasize the iterative nature of certain aspects of the parasite life cycle, including invasion (LeRoch et al., 2003; Hall et al., 2005; Florens et al., 2002) . Both sporozoites and merozoites possess the same complement of invasion-associated organelles, and there is overlap with the ookinete stage in the mosquito, which, however, lacks rhoptries (see Figure 1 , and review article by Cowman and Crabb in this issue of Cell). There may be many invasion proteins shared by merozoites and sporozoites and thus more multistage vac-cine candidates can be proposed. One such multistage vaccine candidate is MAEBL, which is essential for invasion of mosquito salivary glands by sporozoites (Kariu et al., 2002) . MAEBL shares a similar expression pattern to AMA-1 and is a curious hybrid of AMA-1 domains and domains called erythrocyte binding ligands. Indeed detailed, independent transcriptome analyses suggest that many genes encoding proteins that are critical for key events (such as invasion of host or insect cells) are expressed at multiple points in the parasite life cycle.
Post-genome research aided greatly by genetic manipulation of Plasmodium has provided insights into the biology of the parasite and its interactions with both host and vector, which will have implications for vaccine development. For example, functional redundancy among parasite vaccine candidates-such as the P28/P25 family of ookinete surface proteins that are leading transmission blocking candidates for both P. vivax and P. falciparum-cautions against the use of a single protein in vaccine formulations. A single protein may provide sufficient selective pressure to generate mutations (or sequence loss) in the target gene and the proteins encoded by other closely related genes may take up the functional slack resulting in parasites that are immune to antibodies generated by a single protein vaccine (Tomas et al., 2001) . Furthermore, the demonstration that P. falciparum can exploit mechanistically distinct pathways for the invasion of the human erythrocyte will also affect bloodstage vaccine formulations (Stubbs et al., 2005) .
A New Twist to an Old Strategy One very striking post-genome development is a new twist on an old but proven strategy: a vaccine composed of a live-attenuated whole organism. Many studies have shown that vaccination with an attenuated whole parasite generates effective and (in some cases) long-lasting protection in man against both sporozoites (Clyde et al., 1973) and asexual blood stages. In the case of sporozoite vaccination, the parasite is attenuated by irradiation of the live, infected mosquito and administered either through a mosquito bite or by injection of the sporozoites after they have been purified from the irradiated mosquito. Unfortunately, such a vaccine has a number of drawbacks, not the least of which is how to scale up generation of attenuated sporozoites to meet global demand requiring the vaccination of many millions of individuals. However, there are attempts to address this problem as well as the logistics of how to store the attenuated parasites for global distribution (http://www.Sanaria.com). An additional production-line problem is the potential inconsistency of the product: effective irradiation of the sporozoites is absolutely critical to generate an efficacious vaccine. Too little irradiation and the sporozoite will remain infectious and generate a full-blown malaria infection in "vaccinated" subjects; but too much irradiation will kill the parasite, and dead parasites do not generate effective immunity. Immunity is dependent upon the ability of the sporozoite to traverse Kupffer cells of the liver and to initiate an aborted pattern of development in hepatocytes. Thus, immunization with a radiation-attenuated sporozoite carries risks.
An alternative might be a genetically attenuated sporozoite . In two independent studies, three genes have been identified that are exclusively expressed in the sporozoite (all studies have been performed in P. berghei) and that when disrupted give rise to a parasite that is unable to infect mice. The genes are called UIS3, UIS4 (Mueller et al., 2005) , and P36p (van Dijk et al., 2005) , and all of them have homologs in P. falciparum. Sporozoites carrying mutations in these genes are motile, retain the ability to invade hepatocytes in vitro, and are able to form a parasitophorous vacuole (an early postinvasion event). However, the mutant parasites do not develop fully in the infected hepatocyte and instead disappear after 12 hr in culture. This indicates that the mutant parasite unlike its wild-type counterpart may fail to suppress apoptosis of the infected host cell, and indeed this seems to be the case for P36p. Examination of the immunogenicity of these mutant parasites has provided the most promising data for UIS3 and P36p. Both forms of mutant parasite, when used as an immunogen, gave full protection to subsequent challenge with wild-type parasites in two strains of mice, including one that is highly susceptible to infection. It is possible that the failure to suppress apoptosis by the genetically attenuated sporozoites actually stimulates immunogenicity and potentiates the immune response leading to the generation of protective immunity.
Two challenges must now be met: (1) Characterization of the target sporozoite antigens and the effector arms of the immune system that provide protection; (2) The generation and characterization of equivalent mutant sporozoites in P. falciparum. Also, the precise functions of the UIS proteins and P36p need to be elucidated. It is known that UIS4 binds to host apolipoprotein A1 (ApoA1) recruiting it to the host-parasite interface where it recruits sufficient cholesterol for development of the parasitophorous vacuole. In keeping with this hypothesis, the amount of available ApoA1 regulates the number of mature liver stage parasites that develop, and a mouse strain deficient in ApoA1 is completely refractory to P. berghei infection. Increasing knowledge about the protein-protein interactions between host and parasite offers new avenues for antiparasitic strategies.
Genome and post-genome research is providing a treasure trove of potential candidate proteins for a malaria vaccine. The current challenge is to provide further validation of these proteins such that they might enter a pipeline for vaccine development in a rational fashion. Post-genome research can help to rank candidates based upon an agreed set of criteria, for example, the essential nature of the protein and its potential partners in proteinprotein complexes. Yet, however promising the pipeline may sound it is a long and difficult process to develop an effective malaria vaccine, and the parasite is far from posing as a sitting target. In a perfect scenario one could perhaps envisage a malaria vaccine within a decade, but the history of malaria vaccine research should teach us that the nefarious malaria parasite will continue to dodge our greatest efforts.
